Klinefelter syndrome refers to a rare form of the genetic condition where the male child is born with an additional X chromosome. Klinefelter syndrome generally affects males and can adversely affect testicular growth and can result in smaller testicles. Klinefelter syndrome leads to lower production of testosterone. Klinefelter syndrome may lead to a reduction in the muscle mass, reduced facial and body hair, and enlarged breast tissue. The syndrome has different symptoms on different people, and it is a very rare condition. As per the National Human Genome Research Institute, Klinefelter syndrome is found in 1 out of every 500 to 1000 newborn male infants.

The Klinefelter syndrome treatment market is projected to reach USD 1.54 Billion by 2030 at 3.96% CAGR during the forecast period 2022-2030.Owing to these unidentifiable symptoms, the syndrome is hard to diagnose, as per the researchers of national human research institutes. This factor creates a high need for proper diagnosis and treatment methods, leading exponential growth to the global Klinefelter syndrome treatment market. Further, awareness activities undertaken by NIH and FDA towards this syndrome has propelled the market growth for the treatment of Klinefelter syndrome.

Market Segmentation

The global Klinefelter syndrome treatment market is studied for different treatment methods and the end-users of such treatments. Breast tissue removal, fertility treatment, and testosterone replacement therapy are some of the treatments undertaken to tackle the Klinefelter syndrome. Different treatments given under fertility treatment include hormone treatments and surgeries. End-users of such Klinefelter syndrome treatment options are ambulatory surgeries, hospitals and clinics, academic institutes, and medical research institutes.

Detailed Regional Analysis

The global Klinefelter syndrome treatment market report includes an in-depth analysis of regional segments. The regional segments studied include North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.  North America is projected to dictate the global Klinefelter syndrome treatment market. This can be attributed to the market players investing in the development of new drug product innovations. Further, a high presence of treatment centers in the region for this syndrome, along with the rising awareness towards this, among people has contributed to the booming ascension of the Klinefelter syndrome treatment market in the region.

Europe is expected to trail behind North America and garner the second-largest share in the global Klinefelter syndrome treatment market. This can be attributed to the mounting prevalence of geriatric population in Europe. Mounting prevalence of the Klinefelter syndrome is another factor causative of the growth in the Klinefelter syndrome treatment market of Europe. Rising research activities for this syndrome in Europe has proliferated growth rates in the regional market during the assessment period. According to the report by Europe PMC, the prevalence of Klinefelter syndrome in males, in 2017, with breast cancer was found to be around 7.5% which was much higher than the previously recorded 3% rate. This connection is promoting a higher degree of research and development to discover new treatment methods for Klinefelter syndrome.

Asia Pacific’s Klinefelter syndrome treatment market is expected to ascend at the fastest rate during the forecast period. This a be attributed to the changing lifestyles of people residing in the region. Further proliferation observed in the population of the region is another factor responsible for the fast-paced growth of the Klinefelter syndrome treatment market over the assessment period. Mounting awareness among the general public regarding this disorder and burgeoning healthcare expenditure in the region are some of the other factors contributing to the upscaling noted in the APAC’s Klinefelter syndrome treatment market.

Key Players

The Klinefelter syndrome treatment market players are Allergan plc, AbbVie, Inc., Endo Pharmaceuticals, Inc., Kyowa Kirin International plc, Eli Lilly and Company, Mylan N.V., Lupin Pharmaceuticals, and Pfizer, Inc.

Industry Update

July 2019: The world’s first clinic that treats Klinefelter syndrome has opened at Guy’s Hospital, near London Bridge. This clinic has brought together all medical facilities required for a patient’s treatment.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com